Cantor Fitzgerald reiterates Insmed stock rating on Brensupri sales outlook
Cantor Fitzgerald has reiterated an Overweight rating and a $235.00 price target for Insmed Inc. (NASDAQ:INSM), noting that the stock has remained flat as investors await upcoming catalysts. The firm estimates second-quarter Brensupri sales to be around $285 million, based on weekly script data, …